Detalhe da pesquisa
1.
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
J Infect Dis
; 229(1): 19-29, 2024 Jan 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37433021
2.
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
Ann Rheum Dis
; 2024 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38782549
3.
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
J Infect Dis
; 227(1): 71-82, 2022 12 28.
Artigo
Inglês
| MEDLINE | ID: mdl-36259542
4.
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
J Infect Dis
; 223(4): 699-708, 2021 02 24.
Artigo
Inglês
| MEDLINE | ID: mdl-32851411
5.
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
J Infect Dis
; 222(6): 979-988, 2020 08 17.
Artigo
Inglês
| MEDLINE | ID: mdl-32320465
6.
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Liver Int
; 37(9): 1304-1313, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28135777